Plain-English translation of NCT04683653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to radiation therapy for women with endometrial cancer. Instead of the standard longer course of treatment, researchers want to see if delivering the same effective radiation dose over a shorter period of 3–5 weeks is safe and works just as well. Each daily treatment will be slightly stronger, but the total amount of radiation you receive will be similar to standard treatment.
Standard pelvic radiation for endometrial cancer typically takes 5–6 weeks, which can be difficult for patients to complete and can cause side effects. This trial aims to see whether completing the treatment faster—while still being safe and effective—could make it easier for women to finish their treatment and possibly reduce side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive pelvic radiation therapy as an outpatient over 3–5 weeks instead of the standard 5–6 weeks. You will have daily radiation treatments at the hospital or clinic. The trial has two phases: first, doctors will establish the safest dose for this shorter treatment, and then a second group of participants will be followed over time to see how well this shortened treatment works. You will have regular check-in visits with your doctor to report any side effects or symptoms.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States